Novartis develops and produces medicines to address patient needs in disease areas where our experience and knowledge have the greatest potential to improve patient outcomes.

Our broad portfolio of medicines includes treatments in the areas of:

• Ophthalmology
• Neuroscience
• Immunology, Hepatology and Dermatology
• Cardiovascular, Renal and Metabolism
• Oncology, including targeted therapies, immuno-oncology, chimeric antigen receptor T cells (CAR-T) and radioligand therapy
• Gene therapies

We are also a global leader in generic and biosimilar medicines [2], committed to playing a leading role in driving access to medicine worldwide.

Data science and digital technologies

A major focus for the Company is to build our talent, pipeline and capabilities in the digital arena. We are working to transform the way we find and test medicines by harnessing the latest data science and digital technologies.  Our aim is to apply emerging tools at scale to bring treatments to patients faster while reducing costs.

New technology platforms

Our work in advanced therapy platforms centers on broadly applicable tools with the potential to become therapeutic staples and game-changers for patients.

Cell and gene therapies [3]

• Using DNA, RNA or cells to reprogram the body to directly fight disease

Radioligand therapies [4]

• Targeted therapeutics that deliver radiation to tumor cells that express a particular receptor